3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Ovarian Neoplasms
3
Breast Neoplasms
3
Neoplasms
2
Uterine Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoadjuvant Therapy
1
Lung Neoplasms
1
Kenny-Caffey syndrome, Type 1
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Adenocarcinoma
1
Interventions
Cisplatin
86
Radiotherapy
71
Paclitaxel
50
Fluorouracil
38
Carboplatin
36
Drug Therapy
32
Neoadjuvant Therapy
23
toripalimab
19
tislelizumab
18
pembrolizumab
17
camrelizumab
17
Irinotecan
17
Esophagectomy
17
Surgical Procedures, Operative
16
Radiation
16
Docetaxel
16
sintilimab
15
Oxaliplatin
14
130-nm albumin-bound paclitaxel
14
nimotuzumab
11
TP protocol
11
S 1 (combination)
11
Radiotherapy, Intensity-Modulated
11
Cetuximab
11
Capecitabine
11
Albumin-Bound Paclitaxel
10
apatinib
9
Leucovorin
9
Immune Checkpoint Inhibitors
8
nedaplatin
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Esophageal Squamous Cell Carcinoma
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled